CD30.CAR

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameCD30.CAR
Drug Alias NameCD30.CARH-27721
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionTumor necrosis factor receptor superfamily member 8 modulatorsT lymphocyte replacements
TargetsTumor necrosis factor receptor superfamily member 8
Therapy Area/IndicationsLymphoma, T-Cell, PeripheralLymphoma, Large-Cell, AnaplasticLymphoma, B-Cell +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBaylor College Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesGenetix Biotherapeutics IncBaylor College Of Medicine
Inactive CompaniesN/A
Active IndicationsLymphoma, T-Cell, PeripheralLymphoma, Large-Cell, AnaplasticLymphoma, B-Cell +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A